This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Boston Scientific Scimed, Inc.. Active years: 2005-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005-2010
Title: Sam Baldwin: Innovator in Therapeutic Angiogenesis
Introduction
Sam Baldwin is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of therapeutic angiogenesis, focusing on methods to improve blood flow in diseased or damaged tissues. With a total of 2 patents, Baldwin's work has the potential to impact the treatment of various ischemic conditions.
Latest Patents
Baldwin's latest patents include innovative methods for therapeutic angiogenesis through bone marrow-derived cell transplantation. His inventions provide techniques for forming new blood vessels in ischemic tissues, which can enhance blood flow and promote healing. The methods involve isolating autologous bone marrow-mononuclear cells from the subject and transplanting them into the affected area. This process aims to induce vascularization in diseased tissues, offering new hope for patients suffering from myocardial and skeletal muscle ischemia.
Career Highlights
Throughout his career, Baldwin has worked with prominent companies in the medical field, including Boston Scientific Scimed, Inc. and Boston Scientific Corporation. His experience in these organizations has allowed him to develop and refine his innovative approaches to therapeutic angiogenesis.
Collaborations
Baldwin has collaborated with notable professionals in his field, including Keith Allen Robinson and Takafumi Ueno. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Sam Baldwin's work in therapeutic angiogenesis represents a significant advancement in medical science. His innovative methods for improving blood flow in ischemic tissues have the potential to transform treatment options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
